Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Aug 28;13:14086. doi: 10.1038/s41598-023-41115-3

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

ACE2 siRNA blocks rS1p pro-inflammatory effects in human endothelial cells. (A) ACE2 siRNA efficiency. Human endothelial cells (hMEC) were stimulated with rS1p (0.66 μg/mL) for 24 h for assessment of IL-6 (B) and MCP-1 (C) production, ICAM-1 (D) and PAI-1 (E) protein expression, and microparticles formation (F) in the presence or absence of ACE2 siRNA (n = 9). Data are expressed as ± SEM; *p < 0.05 control (Ctl) (non-stimulated cells) vs. rS1p stimulated cells; ^†p < 0.05 rS1p stimulated cells vs. rS1p stimulated cells treated with ACE2 siRNA after student’s t-test (A) or 1-way ANOVA followed by Tukey’s post-hoc test. Original blots are presented in Supplementary Figs. S15, S16 and S17.